Our results suggest NHEJ DNA repair and MEK1/2-ERK1/2 pathways as potential therapeutic targets to overcome chemotherapy resistance and improve clinical outcomes in children with AML. The gene discussed is MAPK3; the disease is acute myeloid leukemia.